Idebenone-Activating Autophagic Degradation of α-Synuclein via Inhibition of AKT-mTOR Pathway in a SH-SY5Y-A53T Model of Parkinson’s Disease: A Network Pharmacological Approach

Table 1

The autodocking details of Idebenone binding to AKT1, AKT2, and MAPK1.

Drug	Targets	PDB ID	Binding energy (kcal·mol^−1)
Idebenone	AKT1	4gv1	−5.23
	AKT2	3d0e	−4.67
	MAPK1	4n0s	−5.14